Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates
12:15pm, Wednesday, 21'st Jan 2026
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite moving lower on Wednesday.
Johnson & Johnson's Q4 Results Beat Revenue Estimates, 2026 Guidance Surpasses Expectations
12:14pm, Wednesday, 21'st Jan 2026
Johnson and Johnson (JNJ) reported fourth-quarter results that aligned with EPS expectations but exceeded revenue estimates. The company's initial 2026 guidance f
J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales
11:30am, Wednesday, 21'st Jan 2026
JNJ beat Q4 earnings and sales estimates as strong oncology drug growth, led by Darzalex, offset biosimilar pressure on Stelara.
OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings
10:00am, Wednesday, 21'st Jan 2026
Johnson & Johnson (JNJ) posted better-than-expected earnings but still traded to the downside. Diane King Hall points to Stelara as the cause.
S&P 500, Nasdaq Futures Pivot Higher on Trump Davos Speech
09:23am, Wednesday, 21'st Jan 2026
Stock futures are pointed mixed this morning, after the major indexes yesterday suffered their biggest drop since October
Johnson & Johnson reports Q4 earnings beat, issues 2026 guidance above forecasts
09:21am, Wednesday, 21'st Jan 2026
Johnson & Johnson (NYSE:JNJ) reported fourth quarter and full-year 2025 results that came in above market expectations and issued 2026 guidance that was modestly ahead forecasts. For Q4, Johnson & J
Johnson & Johnson Shares Fall Despite Q4 Revenue Beat
09:18am, Wednesday, 21'st Jan 2026
J&J (JNJ) stock dipped about 2% after the healthcare giant reported fourth-quarter results that matched EPS expectations but topped revenue forecasts.The compan
5 Things to Know Before the Stock Market Opens
08:35am, Wednesday, 21'st Jan 2026
Stock futures are slightly lower this morning after sinking on Tuesday owing to new tariff threats from President Donald Trump; investors are awaiting Trump's speech today at the World Economic Forum
AtaiBeckley seen as key beneficiary of Spravato’s strong growth: Jefferies
07:58am, Wednesday, 21'st Jan 2026
Jefferies analysts said the continued commercial momentum of Johnson & Johnson (NYSE:JNJ)'s Spravato (esketamine nasal spray) could provide a meaningful...
Breakfast News: Competition Concerns Netflix CEO
07:30am, Wednesday, 21'st Jan 2026
Netflix reaches 325 million subs, futures edge up after tough Tuesday, and more
J&J expects to hit $100 billion in revenue next year after new strategy pays off
07:26am, Wednesday, 21'st Jan 2026
Johnson & Johnson sees revenue grow 9% in the fourth quarter, amid strength in its cancer drugs.
Johnson & Johnson forecasts 2026 profit above Wall Street estimates
06:23am, Wednesday, 21'st Jan 2026
Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of Wall Street estimates, even when including a hit of "hundreds of millions of dollars" from the drug pricing deal it signed
Johnson & Johnson reports Q4 and Full-Year 2025 results
06:20am, Wednesday, 21'st Jan 2026
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. “2025 was a catapult year for Johnson & Johnson, fueled by the stro
J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales
06:20am, Wednesday, 21'st Jan 2026
The healthcare company's forecast for 2026 tops Wall Street's expectations.
Beacon Financial Advisory LLC Lowers Stock Holdings in Johnson & Johnson $JNJ
05:48am, Wednesday, 21'st Jan 2026
Beacon Financial Advisory LLC lessened its position in Johnson and Johnson (NYSE: JNJ) by 63.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commi
